Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jarno Drost

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Cell Reports|June 1, 2026
Mutational signatures of environmental carcinogens in human tissue organoids revealed by duplex sequencingJill E Kucab, Shuvro P Nandi, Halh Al-Serori, et al.
Nature Reviews. Urology|January 1, 2026
Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaborationMichael V Ortiz, Francis S P L Wens, Andrew L Hong, et al.
Nature Communications|March 4, 2021
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumoursLars Custers, Eleonora Khabirova, Tim H H Coorens, et al.
JCO Precision Oncology|May 18, 2026
Systematic Review: Prognostic Molecular Biomarkers in Wilms TumorsAgustina Oller, Patrick Kemmeren, Daniela Perotti, et al.
BMC Cancer|July 3, 2023
Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGSIanthe A E M van Belzen, Casey Cai, Marc van Tuil, et al.
Elife|January 18, 2021
Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cellsIris E Glykofridis, Jaco C Knol, Jesper A Balk, et al.
Journal of Clinical Medicine|December 10, 2021
Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the LiteratureSophie E van Peer, Janna A Hol, Alida F W van der Steeg, et al.
Urologic Oncology|June 22, 2025
Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study groupAlissa Groenendijk, Harm van Tinteren, Ronald R de Krijger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocolsAlissa Groenendijk, Harm van Tinteren, Yilin Jiang, et al.
Cancers|October 14, 2022
Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms TumorsIanthe A E M van Belzen, Marc van Tuil, Shashi Badloe, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Cell Reports|June 1, 2026
Mutational signatures of environmental carcinogens in human tissue organoids revealed by duplex sequencingJill E Kucab, Shuvro P Nandi, Halh Al-Serori, et al.
Nature Reviews. Urology|January 1, 2026
Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaborationMichael V Ortiz, Francis S P L Wens, Andrew L Hong, et al.
Nature Communications|March 4, 2021
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumoursLars Custers, Eleonora Khabirova, Tim H H Coorens, et al.
JCO Precision Oncology|May 18, 2026
Systematic Review: Prognostic Molecular Biomarkers in Wilms TumorsAgustina Oller, Patrick Kemmeren, Daniela Perotti, et al.
BMC Cancer|July 3, 2023
Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGSIanthe A E M van Belzen, Casey Cai, Marc van Tuil, et al.
Elife|January 18, 2021
Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cellsIris E Glykofridis, Jaco C Knol, Jesper A Balk, et al.
Journal of Clinical Medicine|December 10, 2021
Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the LiteratureSophie E van Peer, Janna A Hol, Alida F W van der Steeg, et al.
Urologic Oncology|June 22, 2025
Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study groupAlissa Groenendijk, Harm van Tinteren, Ronald R de Krijger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocolsAlissa Groenendijk, Harm van Tinteren, Yilin Jiang, et al.
Cancers|October 14, 2022
Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms TumorsIanthe A E M van Belzen, Marc van Tuil, Shashi Badloe, et al.
Pageof 9